In the current revised 4th edition of the World Health Organization (WHO) classification, 'other iatrogenic immunodeficiencyassociated lymphoproliferative disorders (Oii-LPDs)' is listed in the last section in the chapter on immunodeficiency-associated lymphoproliferative disorders. Oii-LPDs cover a broad spectrum from benign lesions to lymphoma, and correspond to one of the subtypes in the WHO classification for immunocompetent patients. The WHO classification does not clearly indicate the histological subtype of this disease category; however, the framework of subtype classification is similar to the classification of post-transplant lymphoproliferative disorders, and recent studies have attempted to subcategorize Oii-LPDs that fit this unique disease type. In this review, we provide an overview of B-cell-type Oii-LPDs regarding their histopathology and immunophenotype, genetics and clinical behaviors.
INTRODUCTION
Although advances in medicine have benefitted humans with disease, some patients who are treated using immunosuppressive agents for autoimmune disease develop lymphoproliferative disorders (LPDs). More than a quarter of a century has passed since the recognition of the association between methotrexate (MTX) usage and the occurrence of LPD. 1 In the current WHO classification, these cases are summarized in the chapter entitled "Immunodeficiencyassociated lymphoproliferative disorders" 2 and the definition of other iatrogenic immunodeficiency-associated lymphoproliferative disorders (Oii-LPDs) is "lymphoid proliferations or lymphomas that arise in patients treated with immunosuppressive drugs for autoimmune disease or conditions other than in the post-transplant setting".
Most Oii-LPDs are B-cell lineage LPDs, and Oii-LPDs cover a broad spectrum from benign to malignant lesions. Mucocutaneous ulcers are a newly-described disease entity in the current WHO classification that belongs to B-cell LPDs. A subset of mucocutaneous ulcers belong to Oii-LPDs 3 and will be described in detail by Ikeda et al. in the latter part of this issue. Here, we describe the histological spectrum from benign to malignant Oii-LPDs, mainly focusing on B-cell lineage Oii-LPDs regarding their pathology, genetics and clinical course.
ETIOLOGY OF OII-LPDS
A subset of patients who are administered immunosuppressive drugs for an underlying primary disease subsequently develop Oii-LPD. Among patients with Oii-LPDs, the most common underlying disorder is rheumatoid arthritis and other underlying disorders include dermatomyositis, Sjogren disease, systemic lupus erythematosus, inflammatory bowel disease. Although several large studies have analyzed Oii-LPDs, all of them were restricted to patients who were administered a particular drug, such as MTX, or patients with a specific underlying disease such as rheumatoid arthritis. Thus, the perspective of Oii-LPDs is unclear. Although patients who are administered immunosuppressive drugs are under an immunocompromised condition, the primary autoimmune disease itself is predisposed to cause LPD. For example, a nationwide cohort study revealed that autoimmune Iatrogenic immunodeficiency-associated lymphoproliferative disorders of B-cell type that develop in patients receiving immunosuppressive drugs other than in the post-transplant setting disease increases the risk of non-Hodgkin lymphoma and the overall incidence of lymphoma was approximately two-times higher in patients with an autoimmune disease than in the immunocompetent population. 4, 5 Therefore, the etiology of Oii-LPDs is not simple and may be multifactorial. However, as Oii-LPDs spontaneously regress after discontinuation of the administered immunosuppressive drug, these therapeutic agents indeed provoke LPDs in subsets of patients.
In the current WHO classification, cancer therapy-related LPDs are not included in Oii-LPDs, although there are many case reports and several small case series of patients who developed LPDs after treatment with chemotherapeutic agents for hematological malignancies, including myeloid neoplasms. 6, 7 Pina-Oviedo et al. summarized these cases and reported a high frequency of Epstein-Barr virus (EBV) infection among patients with LPDs, implying that these patients were in an immunocompromised state after receiving chemotherapy. 7 The number of patients with cancer therapyrelated LPDs is insufficient to be recognized as a distinct disease entity, and a systematic analysis is needed to evaluate the immune condition of the host and ascertain a relationship with the particular Oii-LPD.
HISTOPATHOLOGICAL CLASSIFICATION OF OII-LPDS
The current WHO classification of Oii-LPDs does not take into consideration histopathological classification; however, the histological subtype of post-transplant lymphoproliferative disorder (PTLD) was developed based on studies that analyzed Oii-LPDs/MTX-related LPDs. 8 Currently, MTX is the most common reagent associated with the development of Oii-LPDs; therefore, the frequencies of histological subtypes in MTX-LPD generally reflect those in Oii-LPDs. The relative frequencies of histological subtypes, including benign and borderline lesions, and lymphoma among MTX-LPD cases in large cohorts to date are shown in Figure 1A . 9, 10 The most frequent histological subtype of MTX-LPD is the large B-cell (LBCL) type, including diffuse large B-cell lymphoma (DLBCL) with or without EBV infection. Other frequent subtypes are as follows: reactive lymphoid hyperplasia (RH), classic Hodgkin lymphoma (CHL), polymorphic B-cell LPD (poly-LPD), indolent lymphoma including follicular lymphoma, etc. Thus, most MTX-LPD cases are B-cell lineage LPDs.
Benign and borderline lesions of Oii-LPDs
In the category of PTLD in the WHO classification, 8 benign and borderline lesions are described as reactive hyperplasia (RH) and polymorphic B-cell LPD (poly-LPD), respectively. RH and poly-LPD are differentiated according to whether the architecture of the involved tissue is preserved; the architecture of lymphoid tissue is preserved in RH (Figure 2 lesions spontaneously regresses even if the lesions have a population of monoclonal B cells after withdrawal of the immunomodulator agent such as MTX. 9, 11 The frequencies of monoclonality of IGH and karyotypic abnormalities are higher in poly-LPD than in RHs, [9] [10] [11] suggesting multistep lymphomagenesis in the immunocompromised setting from RH to poly-LPD and sequential development to monomorphic LPD, e.g., DLBCL.
In RH, the architecture of the involved tissue is preserved and EBV-infected lymphoplasmacytic cells are present, resulting in the involved tissue being in a local immunocompromised state. EBV-infected cells are usually observed in interfollicular areas but are also found in lymphoid follicles. Proliferation of immunoblasts has also been observed in approximately 40% of these cases, 10 and marked plasmacytic infiltration is a common feature that can be observed in PTLDs.
In poly-LPD, there is a variety of lymphoid cells from small mature lymphocytes and plasma cells to large atypical B-cells, and in some cases, Hodgkin/Reed-Sternberg (H/ RS)-like cells are found in the lesion, which are referred to as "Hodgkin-like lesions". Differential diagnostic points between poly-LPD (Hodgkin-like lesion) and the CHL type are as follows: First, the presence of typical H/RS cells is important to diagnose CHL-type LPD. Second, EBV infection is restricted to H/RS cells in CHL-type LPD, whereas EBV infects a variety of cells from small lymphocytes to large B-cells in B-LPDs. Third, on immunophenotyping, poly-LPD is positive for CD20 and negative for CD15. On the other hand, CHL-type LPD is similar to de novo CHL and is negative or weakly positive for CD20, and up to 60% of cases express CD15 (Table 1 ). Necrosis and fibrosis are often observed in poly-LPDs. However, poly-LPD, including Hodgkin-like lesions, is not a definite disease entity but rather in the spectrum leading to monomorphic malignancy. Therefore, there are patients in whom a differential diagnosis between poly-LPD and CHL-type LPD cannot be made in daily practice. Mucocutaneous ulcer (MCU), a newly-described disease entity in the current WHO classification, is also included in poly-LPDs. MCU will be described in detail by Ikeda et al.
Large B-cell lymphoma-type LPD
Among patients with large B-cell lymphoma (LBCL)-type LPD, proliferation of atypical large B cells has been noted and patients should be subclassified according to the WHO classification of lymphoma in immunocompetent patients. The frequency of each B-cell type in patients with MTX-LPDs is shown in Figure 1B , summarized from two large cohorts. 9, 10 The most frequent histological type corresponding to immunocompetent patients was DLBCL, NOS ( Figure 4) 10 Gion et al., 15 Loo et al. 18 Approximately twothirds of LBCL-type MTX-LPD cases belong to the non-GCB type according to the Hans classification of cell of origin (Table 2) .
EBV in tumor cells was detected in 157 (50.5%) of 311 LBCL-type MTX-LPD cases by Epstein-Barr encoding region (EBER) in situ hybridization, and type I, II or III latent EBV infection was observed in 11.9% (7/59), 59.3% (35/59) and 28.8% (17/59) of cases, respectively ( Figure  1D) . 9, 10, [13] [14] [15] [16] [19] [20] [21] [22] Even if patients have an immunodeficiency background, only half carry EBV in large B-cell-type lymphoma cells. In recent years, there has been growing evidence of activation of the PD-1/PD-L1 axis to escape from immune surveillance. 23 A subset of tumor cells in DLBCL was reported to express PD-L1 and these patients have a poor prognosis, 24 and higher expression of PD-L1 was observed in EBVpositive DLBCL cases than in EBV-negative DLBCL cases. 25 However, there has been no retrospective cohort study of PD-L1 and PD-1 expression in Oii-LPDs, including MTX-LPDs.
Although little is known about genetic alterations in patients with Oii-LPDs, Carreras et al. investigated the genomic profile of 20 cases of DLBCL-type MTX-LPD (MTX-DLBCL) and identified genomic features that are characteristic to MTX-DLBCL, i.e., 3q, 12q and 20p gains, and 13p loss. 14 The gain of 3q to BTLA, PLOD2 and KLHL6, and 12q to SELPG was positively correlated with protein expression, proliferation, and differentiation and maintenance of the microenvironment of MTX-DLBCL. Some of these genomic alterations may be associated with the infiltration of M2-like macrophages and CD8+ T cells in the tumor microenvironment of MTX-DLBCL. However, genetic alterations in patients with MTX-DLBCL are largely unknown. Therefore, further investigation is necessary.
Classic Hodgkin lymphoma-type Oii-LPD
Classic Hodgkin lymphoma (CHL)-type Oii-LPD is a common histological subtype that accounts for approximately 13.3% of Oii-LPDs (Fig. 1A and 1C) . We searched for CHLtype Oii-LPD cases and found 84 previously reported cases. Features of these cases are summarized in Supplementary  Table 1. 1,9,13,15,19,21,22,26-44 The median age of the patients was 58 years (range, 8 to 84 years). The male-to-female ratio was 1:1.7, and this unusual ratio compared with that in immunocompetent cases may have been caused by the present or past history of RA. Fifty-seven (70.4%) of the 81 patients had rheumatoid arthritis and 3 also had another autoimmune disease. Seventy-three (86.9%) of 84 cases of CHL-type Oii-LPDs were treated by MTX, and other immunosuppressive and/or immunomodulating agents, such as TNFα inhibi- These data were obtained from the following reports of case series of MTX-related DLBCL: Tokuhira et al., 9 Kurita et al., 10 Carreras et al., 14 Gion et al., 15 Niitsu et al. 16 ND, not done tors, etanercept, azathioprine, or prednisolone, were coadministered with MTX in 30 (41.1%) of the 73 cases. CHL-type Oii-LPD is characterized by scattered mononuclear and multinucleated giant cells surrounded by a marked variety of infiltrated non-neoplastic inflammatory cells ( Figure 5 ). Although typical cases of CHL-type Oii-LPD are simple to diagnose based on their morphological and immunohistochemical findings, some cases border between poly-LPD and DLBCL-type Oii-LPD. Currently, there is no consensus on the boundary between poly-LPD and DLBCL-type Oii-LPD; this is a similar situation to that for immunocompetent cases of CHL in relation to DLBCL, which is a known category of gray zone lymphoma between CHL and DLBCL. Furthermore, in immunocompromised cases of Oii-LPDs, "Hodgkin-like lesions", as described above, can be found in poly-LPDs and these lesions lead to complications. Immunohistochemical findings revealed a similar pattern of diagnostic markers (CD20, CD30, PAX5 and CD15) between CHL-type Oii-LPDs and de novo CHL. However, CD15 expression in CHL-type Oii-LPDs is lower than that in de novo CHL ( Table 2 , 60% vs. 80-85%). 45 Moreover, on comparison between CHL-type Oii-LPD and poly-LPD, the rate of CD15 expression was higher in CHLtype Oii-LPDs (75-85%) than in B-LPDs (0%). 10 Therefore, CD15 expression may be a differential diagnostic marker. However, it is difficult to distinguish between B-LPD and CHL-type Oii-LPDs in daily practice because both categories are in the same disease spectrum. Therefore, integrative understanding, including analyses of pathology, genetics, and clinical outcome, is needed to clarify this heterogeneous disease in order to provide satisfactory treatment.
Other B cell lymphoma-type Oii-LPDs
Mature B-cell lymphoma-type LPDs other than LBCLtype LPDs account for less than 10% of Oii-LPDs (8.1%, 27/334 cases, Figure 1D ). However, the precise incidence of mature B-cell lymphoma-type LPDs other than LBCL-type LPDs, especially indolent lymphoma, among Oii-LPDs is unknown. A meta-analysis of lymphoma risk by Simon et al. revealed an increased risk in patients with RA. 46 The standardized incidence ratio for all lymphomas was 2.46, and the ratios for Hodgkin lymphoma and non-Hodgkin lymphoma were 2.26 and 3.21, respectively. However, the risk for non-Hodgkin lymphoma in RA patients who were treated using MTX was not significantly higher than that in the general population in France. 22 Although the underlying autoimmune disease results in chronic antigen stimulation and provokes polyclonal lymphocytic proliferation, whether the incidence of lymphoma in patients with autoimmune disease is higher remains controversial.
Regarding mature B-cell lymphoma-type LPDs other than LBCL-type LPDs, only a small number of cases has been reported and the precise frequency is unknown. Furthermore, follicular lymphoma was the most frequent subtype among indolent B-cell lymphoma-type LPDs and only one of 11 cases of follicular lymphoma was positive for EBV on EBER in situ hybridization according to previous reports (Table 3) . 9, 13, 21, 32 Therefore, whether follicular lymphoma developing in autoimmune disease-treated patients develops as Oii-LPD or as a coincidental lesion is unclear. On the other hand, low-grade B-cell lymphoma with plasma cell diff e r e n t i a t i o n , e s p e c i a l l y m a rg i n a l z o n e l y m p h o m a and plasmacytoma, may be related to the immunodeficient background induced by the primary disease or it may be a secondary therapeutic outcome. As the incidence of Oii-LPD is low, further investigation and accumulation of cases are needed.
CONCLUSION
Oii-LPDs cover a broad spectrum regarding their cytological composition, histological variation, immunophenotype, molecular and genetic/genomic findings, and clinical outcome. Furthermore, Natkunam et al. proposed a common framework for immunodeficiency-associated-LPDs irrespective of causative background. This study will improve the use of common terminology in diverse clinical settings and aid in developing novel treatment strategies.
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